Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.33 |
| ▸ | GABRE | P78334 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15915437 | 0.89 | ALOX15 (0.36) | KMT2AALOX15BLMPMP22LMNA | |
| SCHEMBL5611920 | 0.85 | KMT2A (0.41) | KMT2AALOX15BLMPMP22LMNA | |
| SCHEMBL7741404 | 0.79 | ALOX15 (0.32) | ALOX15 | |
| SCHEMBL7258476 | 0.79 | GABRP (0.50) | LMNAGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11785584 | 0.79 | ALDH1A1 (0.41) | KMT2ALMNAGABRPGABRDGABRA1 | |
| SCHEMBL29035549 | 0.77 | GABRP (0.48) | LMNAGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL27949511 | 0.77 | ALOX15 (0.38) | KMT2AALOX15BLMPMP22LMNA | |
| SCHEMBL28741965 | 0.77 | CA1 (0.35) | KMT2AALOX15CYP1A2MEN1EPHX1 | |
| SCHEMBL30104283 | 0.77 | FAAH (0.59) | KMT2AALOX15BLMLMNACYP1A2 | |
| SCHEMBL4137634 | 0.76 | ALOX15 (0.40) | KMT2AALOX15LMNACYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342022-B2 | Compounds in the treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | claimed |
| EP-1458711-B1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2007-07-18 | — | — | EP | claimed |
| US-20050222181-A1 | COMPOUNDS IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | claimed |
| EP-1458711-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003055877-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | claimed |
| EP-2220060-B1 | TETRAHYDROBENZOTHIAZOLE DERIVATIVES | MOTAC NEUROSCIENCE LTD (GB) | 2016-09-14 | — | — | EP | disclosed |
| EP-2880025-A2 | SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2015-06-10 | — | — | EP | disclosed |
| WO-2014019908-A2 | SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-02-06 | — | — | WO | disclosed |
| US-8389555-B2 | Medicaments | MOTAC NEUROSCIENCE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| EP-2220060-A1 | MEDICAMENTS | Motac Neuroscience Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009056805-A1 | MEDICAMENTS | MOTAC NEUROSCIENCE LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
| US-7342022-B2 | Compounds in the treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| EP-1458711-B1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2007-07-18 | — | — | EP | disclosed |
| US-20050222181-A1 | COMPOUNDS IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1458711-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003055877-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222181-A1 | COMPOUNDS IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | GSK3A, GSK3B, PYGB | KMT2A 2456/4885ALOX15 3227/4885BLM 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.